In: NEOPLASMA, vol. 52, no. 3
W. Li - G. Zhou - X. Song - W. Chi - R. Ren - X. Wang
Detaily:
Rok, strany: 2005, 219 - 224
O článku:
Multidrug resistance (MDR) in human cancers is one of the major
causes of failure of chemotherapy. The emergence of
breast cancer resistance protein (BCRP), a member of the ABC
transporter family, has necessitated the development of
antagonists.
To overcome the BCRP-mediated atypical multidrug drug resistance,
two small interfering RNA constructs
(RNAi) targeting two different regions of BCRP mRNA were designed
to inhibit the atypical MDR expression by
transfecting them into MCF-7/MX100 cell lines. The multidrug
resistance index to mitoxantrone and the intensity of
mitoxantrone fluorescence of MCF-7/MX100 decreased after
transfected by pSUPER-BCRP-A and pSUPER-BCRP-B respectively;
the BCRP mRNA level and the BCRP protein level of MCF-7/MX100
decreased after treated with
pSUPER-BCRPs. The two constructed RNAi plasmids could reverse the
atypical mutidrug resistance mediated by BCRP,
but neither can reversed it completely, this may due to low
transfection efficiency and transient transfection.
Ako citovať:
ISO 690:
Li, W., Zhou, G., Song, X., Chi, W., Ren, R., Wang, X. 2005. Modulation of BCRP mediated atypical multidrug resistance
phenotype by RNA interference. In NEOPLASMA, vol. 52, no.3, pp. 219-224. 0028-2685.
APA:
Li, W., Zhou, G., Song, X., Chi, W., Ren, R., Wang, X. (2005). Modulation of BCRP mediated atypical multidrug resistance
phenotype by RNA interference. NEOPLASMA, 52(3), 219-224. 0028-2685.